- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04641078
Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer (DART)
Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer: a Randomized Phase II Trial (DART)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
As of the 2018 EAU guidelines, PSMA PET-CT is now recommended for prostate cancer patients with a rising PSA following local therapy, resulting in an increase in patients with conventional imaging M0, but novel imaging M1-state. This creates a new class of patients for which no clear guidelines exist on the optimal management. It became clear that there is no real consensus nor data on how these patients should be treated.
In 1995, a new approach was proposed, hypothesizing that patients with a limited number of metastases (oligometastases) might benefit from eradication of metastases by means of local therapy, or metastasis-directed therapy. Stereotactic body radiotherapy (SBRT), a novel radiotherapy technique for metastatic and primary prostate cancer treatments, has emerged as a highly precise radiotherapy method able to eradicate small metastases with acceptable toxicity. Nevertheless, responses following SBRT were not always durable. To improve response rates and time to new metastases, additional steps should be taken balancing with potential added toxicity. One of the logical steps would be to combine SBRT with temporary androgen deprivation therapy (ADT) as this combination therapy is standard of care for primary PCa and locally recurrent PCa17. However, ADT, negatively impacts quality of life (QoL) even when used temporary. Anti-androgen or androgen receptor (AR) pathway inhibitors (ARpI) may circumvent these side effects by suppressing AR transcription by competitive inhibition of AR, without lowering systemic testosterone. The current trial will test the combination of darolutamide with SBRT, in oligometastatic recurrent hormone sensitive prostate cancer. We hypothesize that the addition of short-term darolutamide improves metastasis-free survival when added to SBRT without a detrimental impact on the QoL.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Piet Ost, MD, PhD
- Phone Number: 003293323015
- Email: piet.ost@ugent.be
Study Locations
-
-
-
Aalst, Belgium
- Recruiting
- OLVZ Aalst
-
Contact:
- Ruben De Groote, MD
-
Antwerp, Belgium
- Recruiting
- GZA
-
Contact:
- Piet Dirix, MD
-
Brugge, Belgium
- Recruiting
- AZ St-Jan Brugge
-
Contact:
- Sabine Meersschout, MD
-
Brussel, Belgium
- Recruiting
- Institut Jules Bordet
-
Contact:
- François-Xavier Otte, MD
-
Gent, Belgium
- Recruiting
- AZ St-Lucas Gent
-
Contact:
- Lien Van De Voorde, MD
-
Ghent, Belgium
- Recruiting
- Ghent University Hospital
-
Contact:
- Piet Ost, MD, PhD
-
Hasselt, Belgium
- Recruiting
- Jessa Ziekenhuis
-
Contact:
- Leen Noé, MD
-
Kortrijk, Belgium
- Recruiting
- AZ Groeninge
-
Contact:
- Siska Van Bruwaene, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically proven initial diagnosis of adenocarcinoma of the prostate
- Biochemical relapse of PCa following radical local prostate treatment (radical prostatectomy (RP), primary radiotherapy or the combination of RP and prostate bed adjuvant/ salvage radiotherapy) according to the EAU guidelines 2018.
- Following RP, patients with a biochemical relapse are eligible in case a metastatic relapse is detected even in the absence of prior postoperative prostate bed radiotherapy (adjuvant or salvage). In the absence of prior prostate bed radiotherapy, prostate bed radiotherapy is mandatory for all pT3a or higher or patients with a positive margin at time of RP.
- For patients without prior RP that have a suspected local recurrence following primary radiotherapy, a biopsy should confirm local recurrence. Patients with a confirmed local recurrence and metastases are eligible in case they also undergo a local salvage therapy.
- Metastatic relapse on PSMA PET-CT with a maximum of 5 metastases (any M1a, M1b or M1c). Concomitant diagnosis of N1 disease is allowed as long as all lesions are treated with SBRT and the total number of lesions does not exceed 5. PSMA positive lesions will be scored using the MI-RADS scoring system with lesions scored 4 or 5 considered positive19.
- Asymptomatic for metastatic PCa
- Age >= 18 years
- WHO class 0-1
- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- Before patient registration/randomization, written informed consent must be given in accordance with to ICH/GCP, and national/local regulations.
Exclusion Criteria:
- Local relapse in the prostate gland or prostate bed not suitable for a local salvage treatment
- Small cell carcinoma of the prostate
- PSA doubling time >12 months
- Serum testosterone level <50ng/dl or 1.7 nmol/L at time of randomization
- Currently receiving ADT or PSA rise while on active treatment with ADT (LHRH-agonist, LHRH-antagonist, anti-androgen or estrogen) within the past 6 weeks
- Spinal cord compression or impending spinal cord compression
- Metastases in previously irradiated areas precluding safe delivery of SBRT
- Contraindications to darolutamide
- Previous treatment with cytotoxic agent for PCa
- Treatment during the past month with products known to influence PSA levels (e.g. fluconazole, finasteride, corticosteroids,…)
- Other active malignancy, except non-melanoma skin cancer or other malignancies with a documented disease-free survival for a minimum of 3 years.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A
SBRT + 6 months of darolutamide (600 mg b.i.d.)
|
600 mg BID
stereotactic body radiotherapy
|
Other: Arm B
SBRT only
|
stereotactic body radiotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Metastasis-free survival
Time Frame: 2 year
|
Metastasis-free survival is defined as time between randomization and the appearance of a new metastatic recurrence (any M1) as suggested by PET-CT or death due to any cause.
|
2 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical progression-free survival
Time Frame: 2 year
|
Clinical progression-free survival is defined as the time between randomization and the appearance of a new lesion (any N1 or M1), a local recurrence as suggested by PET-CT, symptoms related to progressive PCa, or death due to any cause.
|
2 year
|
Biochemical relapse-free survival
Time Frame: 2 year
|
For patients who had previous RP at initial diagnosis, a biochemical recurrence is defined by any confirmed PSA rise above 0.20 ng/ml with a confirmatory rise at least 2 weeks later.
For patients who had previous RT to the prostate at initial diagnosis, a biochemical recurrence is defined as the nadir + 2ng/ml (Phoenix definition).
Non-responders are considered to have a biochemical recurrence in case a second measurement at least 2 weeks later confirms a rising PSA
|
2 year
|
Time to next systemic therapy
Time Frame: 4 year
|
Time to next systemic therapy is defined as the initiation of any PCa systemic treatment.
Systemic therapy will typically be initiated on progression and/or development of new metastases, but indications are at the discretion of the physician.
|
4 year
|
Castrate resistant-free survival
Time Frame: 4 year
|
Time to castration resistant disease is defined as the time from trial randomization until castration resistant status
|
4 year
|
Prostate cancer-specific survival
Time Frame: 4 year
|
PCa-specific survival will be read as the time from trial randomization to the date of death due to PCa.
|
4 year
|
Overall survival
Time Frame: 4 year
|
Overall survival will be read as the time from trial randomization to the date of death from any cause.
|
4 year
|
Toxicity: acute toxicity
Time Frame: 3 months
|
Radiotherapy toxicity will be assessed according to NCI CTCAE v5.0.
|
3 months
|
Toxicity: late toxicity
Time Frame: 2 year
|
Radiotherapy toxicity will be assessed according to NCI CTCAE v5.0.
|
2 year
|
Patient reported QOL as per EORTC-QLQ C30
Time Frame: 2 year
|
Validated questionnaire assessing different health-related parameters (psychological, physical and social well-being) in cancer patients.
A higher score of a symptom scale or item indicates a worse condition; a higher score of a functional scale or global health status/QoL indicates a better condition.
A clinically meaningful change is defined as a change from baseline of at least 10 points (i.e., about one-half standard deviation) in either direction.
|
2 year
|
Patient reported QOL as per EORTC-QLQ PR25
Time Frame: 2 year
|
Validated questionnaire assessing the health-related QOL of prostate cancer patients.
A higher score of a symptom scale or item indicates a worse condition; a higher score of a functional scale or global health status/QoL indicates a better condition.
A clinically meaningful change is defined as a change from baseline of at least 10 points (i.e., about one-half standard deviation) in either direction.
|
2 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Piet Ost, MD, PhD, University Hospital, Ghent
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BC-06863
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingProstate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
Clinical Trials on Darolutamide
-
BayerCompletedCerebrovascular CirculationUnited Kingdom
-
The First Affiliated Hospital with Nanjing Medical...RecruitingMetastatic Prostate Cancer | Intermitent Anti-androgen TherapyChina
-
Association Pour La Recherche des Thérapeutiques...BayerRecruiting
-
Peking University First HospitalThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical... and other collaboratorsRecruiting
-
AstraZenecaRecruitingProstate CancerUnited States, Spain, United Kingdom, Netherlands, Canada, Australia
-
BayerRecruitingBiochemically Recurrent Prostate CancerAustria, Spain, United States, France, Germany, Taiwan, Denmark, China, Netherlands, Portugal, Japan, Australia, Canada, Hungary, Italy, Finland, United Kingdom, Brazil, Poland, Israel, New Zealand, Sweden, Belgium, Czechia
-
BayerTerminatedProstatic Cancer, Castration-ResistantUnited States
-
BayerActive, not recruitingProstate CancerUnited States, Canada, Japan, Spain, Germany, Belgium, Argentina, Austria, Brazil, Greece, Italy, Russian Federation, Taiwan, China, Denmark, France, Colombia
-
BayerRecruitingCancerKorea, Republic of, Spain, United States, China, Australia, Austria, Belgium, Brazil, Colombia, Czechia, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Japan, Latvia, Lithuania, Netherlands, Peru, Poland, Portugal, Romania, Russian... and more
-
GenesisCare USABayerWithdrawn